Literature DB >> 1127098

Comparison of cylic and linear forms of somatostatin in the inhibiton of growth hormone, insulin and glucagon Secretion.

H Leblanc, S S Yen.   

Abstract

The relative potency of cyclic and linear somatostatin in their inhibitory action on GH, insulin and glucagon secretion was assessed in 7 normal adult men. Administration of linear or cyclic somatostatin as a single intravenous bolus (50 mug) resulted in a prompt and concomitant decline in both insulin and glucagon. While both peptides elicited a quantitatively similar suppression of glucagon secretion, the decline in basal insulin level was greater with the cyclic than with the linear preparation. Both the linear and cyclic form of somatostatin appears to be more potent in the inhibition of insulin than glucagon. No discernable change in plasma glucose and GH levels was observed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1127098     DOI: 10.1210/jcem-40-5-906

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  [Somatostatin -- a review (author's transl)].

Authors:  C Lucke; H J Mitzkat; A von zur Mühlen
Journal:  Klin Wochenschr       Date:  1976-04-01

2.  Structure-activity relationships of eighteen somatostatin analogues on gastric secretion.

Authors:  M P Brown; D H Coy; A Gomez-Pan; B H Hirst; M Hunter; C Meyers; J D Reed; A V Schally; B Shaw
Journal:  J Physiol       Date:  1978-04       Impact factor: 5.182

3.  The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog.

Authors:  A D Cherrington; J L Chiasson; J E Liljenquist; A S Jennings; U Keller; W W Lacy
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

4.  An in vivo model for testing somatostatin suppression of growth hormone release in sheep.

Authors:  C Redekopp; L D Barrier; J H Livesey; R A Donald
Journal:  J Endocrinol Invest       Date:  1980 Jul-Sep       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.